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Nonalcoholic fatty liver disease (NAFLD) has emerged as 
an important health issue of the modern world, due to the 
dramatic increase in its prevalence, which has doubled and 
in some regions tripled in the past decade (1). 
Epidemiological studies, including national health 
surveys, are remarkable instruments for indirectly 
measuring the health status of the general population, as 
well as providing estimations of the mortality and morbidity 
associated with major diseases and delineating global 
risk factors. Recently, Unalp-Arida and Ruhl attempted 
to establish whether NAFLD is associated not only with 
increased liver disease mortality, but overall mortality rates 
in the US. (2). In addition, they explored the role of non-
invasive biomarkers in the prediction of the natural history 
of NAFLD, including mortality rates. For this purpose, 
the authors retrieved data from the National Health 
and Nutrition Examination Survey (NHANES) I–III 
(1988–2011), which included up to 23 years of linked-
mortality data. As a part of their study, Unalp-Arida 
and Ruhl analyzed the Survey-linked National Death 
Index records of 14,527 adults who were negative for 
viral hepatitis B and C, as well as iron overload. Hepatic 
steatosis (HS) was measured by liver ultrasound and 
classical liver function test that were used as surrogate 
indicators of NAFLD. The sample comprised of 7,739 
participants without and 4,494 with NAFLD, 923 of whom 
were classified as having “severe” HS based on imaging 
parameters. Of note, the authors reported 36.2% all-causes 
cumulative mortality rate, 16.3% and 1.1% of which were 
attributed to cardiovascular disease (CVD) and liver disease, 
respectively (2). The results pertaining to patients with 
severe NAFLD are summarized in Figure 1. These 
individuals also had increased body mass index (BMI) 
and waist-to-hip ratio, higher systolic and diastolic blood 
pressure, increased prevalence of type 2 diabetes (T2D) 
and arterial hypertension, elevated C-reactive protein, and 
increased levels of plasma total cholesterol (Figure 1). These 
results reinforce the concept of a shared genetic effect 
between NAFLD and the metabolic syndrome (MetS), 
whereby ~44% of genes associated with NAFLD are 
probably shared by other MetS components, including T2D, 
obesity and hypertension combined (3). As pointed out by 
Unalp-Arida and Ruhl, the PNPLA3 p.I148M variant is one 
of the most extensively studied genetic influences, which 
explains more than 5% of the liver fat variance and NAFLD 
severity (4,5). Another variant associated with NAFLD, 
TM6SF2 p.E167K, is also of interest, as the E-allele, which 
has an overall frequency of up to 93%, is associated with 
higher blood lipids, while the K-allele confers risk for 
NAFLD (6). However, as expected for complex diseases, the 
authors found that exposure to environmental factors, such 
as increased alcohol consumption and decreased physical 
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activity, was significantly different among subjects with and 
without-NAFLD. These results highlight recent knowledge 
gained from, for instance, mendelian randomization studies 
suggesting that alcohol consumption—even in light or 
moderate amounts—increases the risk and severity of 
NAFLD (7). 
Finally,  severe HS was associated with ~4-fold 
risk of mortality for liver-related diseases (2), even if 
specific causes of death could not be clearly described. 
Surprisingly, HS was not independently associated with 
mortality rates of CVD, T2D or even cancer (2). This lack 
of association can be explained by the fact that adjusting 
for comorbidities, which cluster together in the MetS, 
may produce overfitting. It would thus be interesting to 
examine the degree of tolerance among co-variables in the 
adjusted model.
Liver enzymes and mortality rates: shooting the 
messenger
Unalp-Arida and Ruhl have also observed that liver 
enzymes, including alanine (ALT) and aspartate (AST) 
aminotransfeses, and gamma-glutamyltransferase (GGT) 
were associated with increased risk of liver disease-related 
mortality (Figure 1). The hazard ratio (HR) for the levels 
of these enzymes was reported to range from 4.08 to 7.91, 
whereby the lowest values were found for ALT, followed 
by AST, and the highest for GGT. These interesting 
results prompt several questions. For instance, are 
aminotransferases merely markers of liver injury or are they 
indeed surrogate indicators of systemic alterations? 
The use of liver ultrasound and the measurement of 
serum levels of aminotransaminases, which have been—
Figure 1 The risk factors associated with severe hepatic steatosis and related mortality rates. Figure summarizes the results reported by 
Unalp-Arida and Ruhl that reach statistical significance (2), yielded by the analysis of data sourced from the NHANES I–III, 1988–2011, 
including risk factors for NAFLD and mortality rates. The comparison among risk factors and mortality rates was extracted to denote 
differences between patients with severe NAFLD versus those without NAFLD. The value denotes either mean (standard deviation) or 
percentage (%). Results pertaining to liver enzymes are expressed as IU/L, TC and C-RP are expressed in mg/dl, and blood pressure is 
expressed in mmHg. NHANES, National Health and Nutrition Examination Survey; NAFLD, nonalcoholic fatty liver disease; BMI, 
body mass index; WHR, waist-hip ratio; T2D, type 2 diabetes; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactive 
protein; TC, total cholesterol levels; MET, metabolic equivalent; HR, hazard ratio; ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, gamma-glutamyltransferase; AP, alkaline phosphatase. Liver mortality indicates mortality due to liver disease, 
while overall mortality refers to all-causes mortality. 
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if mildly elevated—classically regarded as surrogate 
indicators of serious disease, are both frequently used for 
the diagnosis of NAFLD in epidemiological studies or 
screening programs. Nevertheless, it is known that the 
entire histologic spectrum of NAFLD, including the severe 
clinical picture of nonalcoholic steatohepatitis (NASH) with 
advanced fibrosis, can be seen in individuals with normal 
values of ALT or AST (8). 
Recent explorations on liver gene and protein expression 
changes of aminotransferases, including their corresponding 
isoforms, in patients with NAFLD have introduced a new 
paradigm into the biological role of liver aminotransferases 
in the regulation of the systemic metabolic functioning (9). 
In fact, we have shown that all the intermediate phenotypes 
of the MetS are associated with perturbed liver gene/
protein expression levels of aminotransferases, as well 
as with circulating metabolites derived from the Krebs 
cycle (9). Therefore, rather than a simple biomarker of 
hepatocyte injury, aminotransferases might be regarded 
as sensors of global metabolic deregulation, including 
mitochondrial energetic control (9). 
Taken together, these findings suggest that the levels of 
aminotransferases are sensors of metabolic complications, 
rather than serving merely as biomarkers of liver necrosis. 
This assertion is supported by Unalp-Arida and Ruhl, 
who demonstrated that ALT levels in the highest decile 
are associated with over twice the risk of mortality in age-
adjusted analysis (2), indicating the need for exploring this 
phenomenon through further cohort studies. Likewise, the 
results showing the levels of AST in the highest decile also 
associated with unadjusted all-causes cumulative mortality 
rates (2) should be considered for further analysis of the 
subsequent NHANES-surveys. 
GGT: antioxidant or pro-oxidant biomarker?
Unalp-Arida and Ruhl found serum GGT elevation to be 
related to all-causes mortality (2), as subjects with elevated 
GGT levels had a 1.45-HR of mortality (Figure 1). 
Serum levels of GGT have been traditionally used as 
markers of liver injury, particularly chronic cholestatic 
diseases and liver tumors, as well as alcohol consumption (10). 
Nevertheless, robust epidemiological evidence indicates that 
serum GGT levels are associated with vascular disease (11) and 
all the components of the MetS (10), as well as with kidney 
disease and cancer. Specifically, a recent meta-analysis of 35 
studies including 571,511 controls and 72,196 cases showed 
that serum GGT levels are associated with increased all-
causes mortality, as well as cardiovascular and cancer-related 
mortality (12). What exactly is the biological meaning of these 
epidemiological findings? 
GGT is a membrane-bound enzyme of the external cell 
surface that catalyzes the hydrolysis of gamma-glutamyl 
bonds in gamma-glutamyl compounds such as glutathione, 
its most abundant substrate. In fact, GGT initiates 
extracellular glutathione (GSH) breakdown, providing 
cells with local cysteine supply and contributing to the 
maintenance of the intracellular GSH levels. 
GGT is expressed not only in the liver but also in many 
different tissues, including kidneys, spleen, gut and acinar 
pancreatic cells, among others; nevertheless, the enzymatic 
activity varies considerably across normal tissues (10). Of 
note, the expression of GGT in the liver is ~20% of that 
in kidneys (10). Multiple alternatively spliced variants of 
GGT have been identified; there are also a number of related 
genes present on chromosomes 20 and 22, as well as putative 
pseudogenes for GGT gene on chromosomes 2, 13, and 22.
On the bases of the biological processes in which GGT 
is involved (Table 1), it has been suggested that this enzyme 
Table 1 List of biological process associated with gamma-
glutamyltransferase (GGT) activity
GO: Biological process Source
Cellular amino acid metabolic process ProtInc
Cysteine biosynthetic process UniProtKB
Glutamate metabolic process UniProtKB
Glutathione biosynthetic process UniProtKB
Glutathione catabolic process UniProtKB
Glutathione metabolic process UniProtKB
Leukotriene biosynthetic process UniProtKB
Leukotriene metabolic process Reactome
Regulation of immune system process UniProtKB
Regulation of inflammatory response UniProtKB
Spermatogenesis UniProtKB
Xenobiotic metabolic process Reactome
Zymogen activation Reactome
GO (Gene ontology) for biological process defines concepts/
classes used to describe gene function and relationships 
between these concepts. Biological processes refer to pathways 
and larger processes comprising of the activities of multiple 
gene products (http://www.geneontolgy.org/).
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plays an important role in protecting cells against oxidative 
stress. This concept is also supported by the effect/s of 
GGT deficiency observed in experimental models, including 
knockout mice (10).
However,  authors  of  some extant  studies  have 
pointed out the potential involvement of GGT in the 
production of reactive oxidative species (ROS) by inducing 
NF-kB-binding (13). In fact, it was shown that, in the 
presence of molecular oxygen and iron or copper ions, GGT 
might be involved in the generation of ROS (14). The high 
GGT activity of preneoplastic hepatic foci produced in rats 
by chemical carcinogens would support this concept (10). 
Regardless of whether GGT is pro- or anti-antioxidant, it 
is clear that serum levels of this enzyme provide information 
on pathways that are relevant for the cellular homeostasis. 
Moreover, serum GGT levels are remarkable surrogate 
of disease-associated pathways, including regulation of 
inflammatory and immune system processes, and xenobiotic 
metabolism, as shown in Table 1. 
On the other hand, the synthesis of GSH from glutamate, 
cysteine, and glycine also highlights the intricate metabolic 
derangement associated with NAFLD and the MetS, which 
involves branched-chain amino acids and glutamine (15). It 
is thus not surprising that, while GSH-associated pathways 
occur in virtually all cell types, the liver is the major organ in 
both GSH production and its exporting. Hence, circulating 
GGT levels may be reliable surrogate indicators of cellular 
stress, whereby they either denote abnormal turnover rates 
of GSH or high levels of enzymatic induction of GGT as 
a mechanism protecting the cell against an imbalance in 
GSH levels (10). When these findings are considered jointly, 
it is plausible to assume that GGT serum levels provide 
information on the whole body stress-associated homeostasis; 
consequently, elevated GGT levels in the serum correlate 
with the incidence and prevalence of a myriad of common 
diseases, including CVD and cancer, and thereby with the 
risk of all-cause mortality.
In summary, the results reported here are truly 
demonstrative of the complexity of the natural history of 
NAFLD, which would without any intervention progress 
to a more detrimental form and thus requires immediate 
intervention. 
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